Picture of Corteva logo

CTVA — Corteva News Story

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsBalancedLarge CapSuper Stock

Corteva Q1 revenue beats analyst estimates on higher volumes

Overview

Global agriculture company's Q1 revenue grew 11% yr/yr, beating analyst expectations

Adjusted EPS for Q1 rose 33% yr/yr

Company plans to repurchase $500 mln of shares in first half of 2026

Outlook

Corteva reaffirms 2026 operating EBITDA guidance of $4.0 bln to $4.2 bln

Company expects 2026 operating EPS of $3.45 to $3.70

Corteva anticipates resilient demand and manageable impact from geopolitical and trade developments

Result Drivers

SEED VOLUME AND MIX - Seed sales rose on higher volumes, improved product mix, and favorable currency, with North America and EMEA gains driven by timing shifts and favorable weather

CROP PROTECTION VOLUME - Crop Protection sales increased on higher volumes from new products and spinosyns, though price declined in Latin America and APAC due to competition

PRODUCTIVITY AND COST INITIATIVES - Ongoing productivity and cost initiatives supported margin expansion across both businesses

Company press release: ID:nPn6TVD08a

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueBeat$4.91 bln$4.64 bln (13 Analysts)
Q1 Adjusted EPS$1.50
Q1 EPS$1.07
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell" The average consensus recommendation for the agricultural chemicals peer group is "buy" Wall Street's median 12-month price target for Corteva Inc is $87.00, about 6.5% above its May 4 closing price of $81.69 The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 20 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Corteva

See all news